Vericel

This content is intended for Health Care Professionals in the United States.

Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. Vericel markets MACI® (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.

For more information, please visit MACI.com.

Loading...